Lista de obras - Adrian Curran - Dominio Público Uruguay

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

artículo científico publicado en 2009

Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.

artículo científico publicado en 2011

Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up

artículo científico publicado en 2008

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen

article

Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome

artículo científico publicado en 2008

Body composition changes after switching from protease inhibitors to raltegravir

article

Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO Trial

article

Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).

artículo científico publicado en 2010

Current role of tenofovir in clinical medicine

artículo científico publicado en 2008

Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients

artículo científico publicado en 2015

Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis

artículo científico publicado en 2013

Darunavir as first-line therapy. The TITAN study

artículo científico publicado en 2008

Double-boosted protease inhibitor antiretroviral regimens: what role?

scientific article published on January 2008

Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen

article

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

artículo científico publicado en 2014

Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients.

artículo científico publicado en 2007

Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study

artículo científico publicado en 2007

Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group

artículo científico publicado en 2014

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.

artículo científico publicado en 2010

Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

article

Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.

artículo científico publicado en 2010

Epidemiology and diagnosis of tuberculous lymphadenitis in a tuberculosis low-burden country

artículo científico publicado en 2015

Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literature

artículo científico publicado en 2015

Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab

artículo científico publicado en 2019

From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir ⬇️

artículo científico publicado el 17 de enero de 2011

HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin

artículo científico publicado en 2011

HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain

artículo científico publicado en 2009

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).

artículo científico publicado en 2015

Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.

artículo científico publicado en 2014

Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment

artículo científico publicado en 2016

Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease

artículo científico publicado en 2009

Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.

artículo científico publicado en 2013

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

artículo científico publicado en 2008

Invasive pneumococcal disease in HIV Infected adults. Clinical changes after the introduction of the pneumococcal conjugate vaccine in children

article

LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy

artículo científico publicado en 2012

Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients

artículo científico publicado en 2014

Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir

artículo científico publicado en 2011

Management of tuberculosis in HIV-infected patients.

artículo científico

Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital

artículo científico publicado en 2012

Non-tuberculous mycobacteria in the sputum of HIV-infected patients: infection or colonization?

artículo científico publicado en 2009

Peak bone mass in young HIV-infected patients compared with healthy controls

artículo científico publicado en 2014

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis

article

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

artículo científico publicado en 2009

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC.

artículo científico publicado en 2014

Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial

artículo científico publicado en 2014

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.

artículo científico publicado en 2009

Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat

artículo científico

Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM.

artículo científico publicado en 2015

Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients

artículo científico publicado en 2012

Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.

artículo científico publicado en 2014

The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men.

artículo científico publicado en 2015

The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial

artículo científico publicado en 2015

Tropical diseases screening in immigrant patients with human immunodeficiency virus infection in Spain.

artículo científico publicado en 2013

Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients

artículo científico publicado en 2013

Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.

artículo científico publicado en 2013

Lista de obras de Adrian Curran

A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.

Abacavir coadministration does not interfere with the suppressive activity of ribavirin in an HCV replicon system.

Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up

Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen

Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome

Body composition changes after switching from protease inhibitors to raltegravir

Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO Trial

Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).

Current role of tenofovir in clinical medicine

Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients

Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis

Darunavir as first-line therapy. The TITAN study

Double-boosted protease inhibitor antiretroviral regimens: what role?

Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients.

Effectiveness of polysaccharide pneumococcal vaccine in HIV-infected patients: a case-control study

Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.

Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients.

Epidemiology and diagnosis of tuberculous lymphadenitis in a tuberculosis low-burden country

Epidemiology and long-term survival in HIV-infected patients with Pneumocystis jirovecii pneumonia in the HAART era: experience in a university hospital and review of the literature

Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab

From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir ⬇️

HIV and TB coinfection: using adjusted doses of lopinavir/ritonavir with rifampin

HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain

Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).

Impact of an adherence program to antiretroviral treatment on virologic response in a cohort of multitreated and poorly adherent HIV-infected patients in Spain.

Impact of low-level viraemia on virological failure in HIV-1-infected patients with stable antiretroviral treatment

Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease

Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.

Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).

Invasive pneumococcal disease in HIV Infected adults. Clinical changes after the introduction of the pneumococcal conjugate vaccine in children

LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy

Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients

Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir

Management of tuberculosis in HIV-infected patients.

Neurological opportunistic infections and neurological immune reconstitution syndrome: impact of one decade of highly active antiretroviral treatment in a tertiary hospital

Non-tuberculous mycobacteria in the sputum of HIV-infected patients: infection or colonization?

Peak bone mass in young HIV-infected patients compared with healthy controls

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis

Raltegravir, etravirine, and ritonavir-boosted darunavir: a safe and successful rescue regimen for multidrug-resistant HIV-1 infection.

Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC.

Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trial

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.

Rezolsta® (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat

Risk of progression to high-grade anal intraepithelial neoplasia in HIV-infected MSM.

Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients

Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.

The effectiveness of electrocautery ablation for the treatment of high-grade anal intraepithelial neoplasia in HIV-infected men who have sex with men.

The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial

Tropical diseases screening in immigrant patients with human immunodeficiency virus infection in Spain.

Ultrasensitive real-time PCR for the clinical management of visceral leishmaniasis in HIV-Infected patients

Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study.